Minocycline, A Tetracycline Derivative, as a Potential Protective Agent for Acute Stroke

Koistinaho, Jari; Koistinaho, Milla

doi:10.1007/978-1-4614-8915-3_15

Cited by 2 publications

(1 citation statement)

References 74 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the effectiveness of minocycline in treating negative symptoms has been identified, its mechanism of action remains unresolved [ 22 ]. Three possible mechanisms of action have been posited: Neuroprotection against grey matter loss: minocycline may directly prevent neurodegeneration of grey matter in individuals with psychosis.…”

Section: Introductionmentioning

confidence: 99%

The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial

Lisiecka

Suckling

Barnes

et al. 2015

Trials

View full text Add to dashboard Cite

BackgroundNegative symptoms of psychosis do not respond to the traditional therapy with first- or second-generation antipsychotics and are among main causes of a decrease in quality of life observed in individuals suffering from the disorder. Minocycline, a broad-spectrum tetracyclic antibiotic displaying neuroprotective properties has been suggested as a new potential therapy for negative symptoms. In the two previous clinical trials comparing minocycline and placebo, both added to the standard care, patients receiving minocycline showed increased reduction in negative symptoms. Three routes to neuroprotection by minocycline have been identified: neuroprotection against grey matter loss, anti-inflammatory action and stabilisation of glutamate receptors. However, it is not yet certain what the extent of the benefit of minocycline in psychosis is and what its mechanism is. We present a protocol for a multi-centre double-blind randomised placebo-controlled clinical trial entitled The Benefit of Minocycline on Negative Symptoms of Psychosis: Extent and Mechanism (BeneMin).MethodsAfter providing informed consent, 226 participants in the early phase of psychosis will be randomised to receive either 100 mg modified-release capsules of minocycline or similar capsules with placebo for 12 months in addition to standard care. The participants will be tested for outcome variables before and after the intervention period. The extent of benefit will be tested via clinical outcome measures, namely the Positive and Negative Syndrome Scale score, social and cognitive functioning scores, antipsychotic medication dose equivalent and level of weight gain. The mechanism of action of minocycline will be tested via blood screening for circulating cytokines and magnetic resonance imaging with three-dimensional T1-weighted rapid gradient-echo, proton density T2-weighted dual echo and T2*-weighted gradient echo planar imaging with N-back task and resting state. Eight research centres in UK and 15 National Health Service Trusts and Health Boards will be involved in recruiting participants, performing the study and analysing the data.DiscussionThe BeneMin trial can inform as to whether in minocycline we have found a new and effective therapy against negative symptoms of psychosis.The European Union Clinical Trial Register: EudraCT 2010-022463-35 with the registration finalised in July 2011. The recruitment in the trial started in January 2013 with the first patient recruited in March 2013.

show abstract

Section: Introductionmentioning

confidence: 99%

The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial

Lisiecka

Suckling

Barnes

et al. 2015

Trials

View full text Add to dashboard Cite

show abstract

Molecular Pathways of Ischemic Stroke and Advanced Therapeutic Strategies

Singh¹

2018

IJSTS

View full text Add to dashboard Cite

Ischemic stroke is a leading cause of death and permanent disability. This disease may affect any age group and especially in old age and pregnancy. All the responsible mechanisms are yet not completely understood. There is limited therapeutic intervention beyond prevention, yet tremendous progress in understanding cause of stroke at molecular level has been going on. A lot of advancement has occurred in the prevention and treatment of stroke during the past decade. In this review an update work of causeways of stroke and its therapeutic approaches have been discussed. The relevance of excitotoxicity (role of glutamate receptor), inflammation, ischemic penumbra, apoptosis, to delayed mechanisms and, damage and treatment strategies have been hasted out. Although the results among clinical studies, conflict regarding several experimental data of different therapies, and it may improve neurological outcome after acute cerebral ischemia. Along this several other interventions and new technologies such as stroke detector microwave helmet are being assessed and many other advanced techniques developed by researchers. Even the development of other novel and new treatment strategies (regarding molecular pathways and risk to benefit therapeutic ratio) for stroke are still required in future for better treatment.

show abstract

Minocycline, A Tetracycline Derivative, as a Potential Protective Agent for Acute Stroke

Cited by 2 publications

References 74 publications

The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial

The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial

Molecular Pathways of Ischemic Stroke and Advanced Therapeutic Strategies

Contact Info

Product

Resources

About